BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Medical Device Firm TherOx Files for $100 Million IPO


9/5/2008 6:45:13 AM

IRVINE, Calif., Sept. 4 /PRNewswire/ -- TherOx, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock.

Citigroup Global Markets Inc. and UBS Investment Bank are acting as joint book-running managers for the offering with Cowen and Company, LLC and Wachovia Capital Markets, LLC acting as co-managers. The number of shares to be offered by TherOx and the price range for its shares have yet to be determined.

The offering of common stock will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from either Citigroup Global Markets Inc., Brooklyn Army Terminal, 140 58th Street, Brooklyn, New York 11220, Attn: Prospectus Department or UBS Investment Bank, Attn: Prospectus Department, 299 Park Avenue, New York, New York 10171.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell nor the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of the securities under the securities laws of any such state or jurisdiction.

About TherOx, Inc.

TherOx is a medical device company that is focused on designing, developing and marketing products that implement its proprietary Supersaturated Oxygen System to salvage heart muscle in acute heart attack patients. TherOx's Supersaturated Oxygen System has not yet received FDA approval and is currently limited by United States law to investigational use only.

CONTACT: Kevin T. Larkin, President and Chief Executive Officer, or
Shelley B. Thunen, Chief Financial Officer, both of TherOx, Inc.,
+1-949-757-1999



Read at BioSpace.com
Read at Reuters

TherOx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES